Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: The Observational Study of Severe Osteoporosis (OSSO)

QJM: An International Journal of Medicine

Volumn 99, Issue 8, 2006, Pages 531-543

  Jakob, F ^a   Marin F ^b   Martin Mola E ^c   Torgerson, D ^d   Fardellone, P ^e   Adami, S ^f   Thalassinos, N C ^g   Sykes, D ^b   Melo Gomes, J ^h   Chinn, C ^b   Nicholson, T ^b   Cooper, C ⁱ  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d UNIVERSITY OF YORK   (United Kingdom)

^e AMIENS UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF VERONA   (Italy)

^g EVANGELISMOS HOSPITAL   (Greece)

^h INSTITUTO PORTUGUÊS DE REUMATOLOGIA   (Portugal)

ⁱ SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; ETIDRONIC ACID; FLUORIDE; GESTAGEN; GLUCOCORTICOID; HEPARIN; INSULIN DERIVATIVE; ORAL ANTIDIABETIC AGENT; PAMIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; THYROID HORMONE; TIBOLONE;

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; BONE FRAGILITY; BREAST DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; EXERCISE; FALLING; FEMALE; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HOT FLUSH; HUMAN; LEG CRAMP; LUMBAR SPINE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RHINITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SIDE EFFECT; SPINE FRACTURE; THROMBOEMBOLISM; TREATMENT OUTCOME; UTERUS BLEEDING; VIRILIZATION;

EID: 33748110296     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcl073     Document Type: Article

References (50)

1. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359:1929-36.
2. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11:556-61.
3. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B. Mortality after osteoporotic fractures. Osteoporos Int 2004; 15:38-42.
4. Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12:24-35.
5. Lippuner K, Golder M, Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. 2004; 16(Suppl. 2):8-17.
6. Levy P, Levy E, Audran M, Cohen-Solal M, Fardellone P, Le Parc JM. The cost of osteoporosis in men: The French situation. Bone 2002; 30:631-6.
7. Marcus R, Wong M, Heath H, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002; 23:16-37.
8. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-41.
9. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomised controlled trial. JAMA 1999; 282:1344-52.
10. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11:83-91.
11. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. JAMA 1999; 282:637-45.
12. Chesnut CH, 3rd, Silverman S, Andriano K, et al. A randomised trial of nasal spray calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000; 109:267-76.
13. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350:459-68.
14. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9:461-8.
15. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-41.
16. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart A. Compliance with osteoporosis medications. Arch Inter Med 2005; 165:2414-19.
17. Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation. J Manag Care Pharm 1998; 4:488-92.
18. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003; 14:259-62.
19. Turbi C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguelez R, Sacristan J, Marin F. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther 2004; 26:245-56.
20. Davies GC, Huster WJ, Lu Y, Plouffe L, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999; 93:558-65.
21. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B. Early discontinuation of treatment for osteoporosis. Am J Med 2003; 115:209-16.
22. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders among women using alendronate for osteoporosis. Am J Manag Care 1998; 4:1377-82.
23. NICE Guideline TA087. The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women. [http://www.nice.org.uk/page.aspx?o=115560]
24. Läkemedelsförmånsnämnden. Forsteo får fortsatt subvention med ny begränsning. [http://www.lfn.se/LFNTemplates/Ptjanst_1146.aspx]
25. Lems WF, Hamdy NAT, Netelenbos JC. Teriparatide: An anabolic drug for the treatment of patients with osteoporosis. Ned Tijdschr Geneeskd 2006; 150:132-7.
26. Lewiecki EM. Nonresponders to osteoporosis therapy. J Clin Densitom 2003; 6:307-14.
27. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112:281-9.
28. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationship between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002; 17:1-10.
29. Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: Reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 2005; 20:2097-104.
30. Carey JJ. What is a failure of bisphosphonate therapy for osteoporosis?. Cleve Clin J Med 2005; 72:1033-9.
31. Lips P, Cooper C, Agnusdei D, Caulin F, Egger P, Johnell O, Kanis JA, Liberman U, Minne H, Reeve J, Reginster JY, de Vernejoul MC, Wiklund I. Quality of life as outcome in the treatment of osteoporosis: The development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporos Int 1997; 7:36-8.
32. Brooks R. EuroQoL: The current state of play. Health Policy 1996; 37:53-72.
33. Roux C, Garnero P, Thomas T, Sabatier JP, Orcel P, Audran M. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Joint Bone Spine 2005; 72:26-31.
34. Heckman GA, Papaioannou A, Sebaldt RJ, Ioannidis G, Petrie A, Goldsmith C, Adachi JD. Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. BMC Musculoskelet Disord 2002; 3:6-23.
35. Josse RG, Sawka AM, Ioannidis G, Murray TM, Sebaldt RJ, Hanley DA, Brown JP, Goldsmith CH, Papaioannou A, Olszynski WP, Petrie A, Adachi JD. Predictors of early failure of bisphosphonate therapy in patients registered in the Canadian database of osteoporosis and osteopenia (CANDOO) [abstract]. Calcif Tissue Int 2003; 72:397.
36. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK. Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26:688-703.
37. Francis RM. Non-response to osteoporosis treatment. J Br Menopause Soc 2004; 10:76-80.
38. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15:1003-8.
39. Marshall JK. The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opin Drug Saf 2002; 1:71-8.
40. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, Berger M. Patients with prior fracture have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15:721-39.
41. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285:320-3.
42. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35:375-82.
43. Oleksik AM, Ewing S, Shen W, van Schoor NM, Lips P. Impact of incident vertebral fractures on health-related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos Int 2004; 16:861-70.
44. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. University of York, Centre for Health Economics, 1999. Discussion Paper 172.
45. Beard CM, Melton LJ III, Cedel SL, Richelson LS, Riggs BL. Ascertainment of risk factors for osteoporosis: Comparison of interview data with medical record review. J Bone Miner Res 1990; 5:691-9.
46. Ismail AA, O'Neill TW, Cockerill W, Finn JD, Cannata JB, Hoszowski K, Johnell O, Matthis C, Raspe H, Raspe A, Reeve J, Silman AJ. Validity of self-report of fractures: Results from a prospective study in men and women across Europe. Osteoporos Int 2000; 11:248-54.
47. Nevitt MC, Cummings SR, Browner WS, Seeley DG, Cauley JA, Vogt TM, Black DM. The accuracy of self-report of fractures in elderly women: Evidence from a prospective study. Am J Epidemiol 1992; 135:490-9.
48. O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ. The prevalence of vertebral deformity in European men and women: The European Vertebral Osteoporosis Study. J Bone Miner Res 1996; 11:1010-18.
49. Elffors I, Allander E, Kanis JA, et al. The variable incidence of hip fracture in southern Europe: The MEDOS study. Osteoporos Int 1994; 4:253-63.
50. Ismail AA, Pye SR, Cockerill WC, et al. Incidence of limb fracture across Europe: Results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 2002; 13:565-71.